MYCOPHENOLATE MOFETIL HYDROCHLORIDE

Post-LOE

mycophenolate mofetil hydrochloride

Roche

ANDAINJECTIONINJECTABLE

Approved

Feb 2017

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

MYCOPHENOLATE MOFETIL HYDROCHLORIDE (mycophenolate mofetil hydrochloride) by Roche is (mmf) is absorbed following oral administration and hydrolyzed to mycophenolic acid (mpa), the active metabolite. Approved for organ rejection, older of allogeneic kidney [see ], heart [see ] and 6 more indications. First approved in 2017.

Drug data last refreshed 18h ago

Mechanism of Action

(MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is a selective uncompetitive inhibitor of the two isoforms (type I and type II) of inosine monophosphate dehydrogenase (IMPDH) leading to inhibition of the de novo pathway of…

Indications (6)

Worked on MYCOPHENOLATE MOFETIL HYDROCHLORIDE at Roche? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.